SEC63: A Protein with Potential in Cancer Treatment (G11231)

Target Name: SEC63

NCBI ID: G11231

SEC63

SEC63: A Protein with Potential in Cancer Treatment

SEC63 (SEC63L) is a protein that is expressed in various tissues throughout the body. It is a key regulator of cell division and has been implicated in the development and progression of many diseases, including cancer. As a drug target or biomarker, SEC63 has significant potential in the development of new treatments for a variety of diseases.

SEC63 is a transcription factor that plays a critical role in the regulation of gene expression. It is a transcription factor that is expressed in a wide variety of tissues, including muscle, heart, liver, and brain. It is highly expressed in fetal tissues and has been shown to be involved in the regulation of cell proliferation, differentiation, and apoptosis.

One of the most significant functions of SEC63 is its role in cell division. SEC63 is a key regulator of the G1/S transition, which is the process by which a cell prepares for cell division. During the G1/S transition, SEC63 helps to ensure that the cell has enough copies of its chromosomes to divide correctly. It also helps to ensure that the cell division process is properly regulated, which is critical for the growth and development of tissues.

In addition to its role in cell division, SEC63 is also involved in the regulation of cell apoptosis. Apoptosis is a natural process that is involved in the elimination of damaged or dysfunctional cells. SEC63 is shown to play a key role in the regulation of apoptosis, as it has been shown to promote the formation of apoptotic cells. This is important for the development and progression of diseases, as the elimination of damaged cells is critical for overall tissue health.

SEC63 is also involved in the regulation of cell signaling pathways. It is a key regulator of the TGF-β pathway, which is a signaling pathway that is involved in the regulation of cell growth, differentiation, and apoptosis. TGF-β is a potent regulator of cell growth and has been implicated in the development and progression of many diseases, including cancer. SEC63 plays a critical role in the regulation of TGF-β signaling, as it has been shown to inhibit the activity of TGF-β.

As a drug target or biomarker, SEC63 has significant potential in the development of new treatments for a variety of diseases. For example,SEC63 has been shown to be a potential therapeutic target for the treatment of cancer, as it has been shown to inhibit the activity of TGF-β. Additionally, SEC63 has been shown to be involved in the regulation of cell apoptosis, which is a critical process for the elimination of damaged cells. This suggests that SEC63 may be a useful biomarker or drug target for the treatment of diseases that are characterized by the rapid growth and development of cancer cells.

In conclusion, SEC63 is a protein that plays a critical role in the regulation of cell division, apoptosis, and signaling pathways. As a drug target or biomarker, SEC63 has significant potential in the development of new treatments for a variety of diseases. Further research is needed to fully understand the functions of SEC63 and its potential as a therapeutic target or biomarker.

Protein Name: SEC63 Homolog, Protein Translocation Regulator

Functions: Mediates cotranslational and post-translational transport of certain precursor polypeptides across endoplasmic reticulum (ER) (PubMed:22375059, PubMed:29719251). Proposed to play an auxiliary role in recognition of precursors with short and apolar signal peptides. May cooperate with SEC62 and HSPA5/BiP to facilitate targeting of small presecretory proteins into the SEC61 channel-forming translocon complex, triggering channel opening for polypeptide translocation to the ER lumen (PubMed:29719251). Required for efficient PKD1/Polycystin-1 biogenesis and trafficking to the plasma membrane of the primary cilia (By similarity)

The "SEC63 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SEC63 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets